Finance

Lists
PACS:NYSE
PACS Group Inc
$48.32
+0.52%
(+0.25) 1D
$48.32
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:03 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PACS...
Open
$48.32
High
$48.47
Low
$47.24
Mkt. cap
7.67B
Avg. vol.
877.21K
Volume
464.46K
P/E ratio
28.07
52-wk high
$51.68
52-wk low
$10.31
EPS
$1.72
Shares outstanding
158.72M
No. of employees
47K
Open
$48.32
High
$48.47
Low
$47.24
Mkt. cap
7.67B
Avg. vol.
877.21K
Volume
464.46K
P/E ratio
28.07
52-wk high
$51.68
52-wk low
$10.31
EPS
$1.72
Shares outstanding
158.72M
No. of employees
47K
News stories
From web sources and news partners
About PACS Group Inc
CEO-
Employees47.5K
Founded2013
HeadquartersSalt Lake City, Utah, United States
SectorHealth Care
IndustryHealth care provider
Websitepacs.com
Analyst ratings
Based on 5 analysts giving stock ratings to PACS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for PACS in the last 3 months.
Highest
Current $48.32
$67.00 (+38.66%)
Average
$61.50 (+27.28%)
Lowest
$57.00 (+17.96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Wiederhorn
Oppenheimer
Buy
Maintained
$57.00
+18%
11/10/2026
A.J. Rice
UBS
Buy
Reiterated
$67.00
+38.7%
11/05/2026
Unknown Analyst
Stephens
Buy
Maintained
$64.00
+32.5%
11/05/2026
Benjamin Rossi
J.P. Morgan
Buy
Reiterated
$58.00
+20%
09/08/2026
David S Macdonald
Truist Financial
Buy
Maintained
-
-
09/02/2026
Ben Hendrix
RBC Capital
Buy
Reiterated
$57.00
+18%
08/05/2026
Jailendra Singh
Truist Financial
Buy
Reiterated
$52.00
+7.6%
06/15/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
$0.63 / $0.58
+8.09%beat
Revenue / Est. (USD)
1.50B / 1.46B
+2.88%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.36B
1.42B
1.43B
1.50B
Cost of goods sold
1.12B
1.16B
1.17B
1.23B
Cost of revenue
1.12B
1.16B
1.17B
1.23B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
123.29M
122.45M
124.74M
150.14M
Operating expense
138.67M
140.52M
144.86M
170.22M
Total operating expenses
1.26B
1.30B
1.32B
1.40B
Operating income
94.69M
120.04M
109.33M
99.72M
Other non operating income
-99.00K
-330.00K
1.82M
-3.64M
EBT including unusual items
86.81M
113.74M
105.84M
91.31M
EBT excluding unusual items
86.81M
113.74M
105.84M
91.31M
Income tax expense
27.03M
33.07M
29.49M
30.50M
Effective tax rate
31.13%
29.07%
27.86%
33.40%
Other operating expenses
-
-
-
-
Net income
59.70M
80.70M
76.37M
60.82M
Net profit margin
4.40%
5.68%
5.35%
4.06%
Earnings per share
0.57
0.64
0.63
0.63
Interest and investment income
-
-
-
-
Interest expense
-8.58M
-6.42M
-6.04M
-5.10M
Net interest expenses
-8.58M
-6.42M
-6.04M
-5.10M
Depreciation and amortization charges
15.38M
18.08M
20.12M
20.08M
EBITDA
110.07M
138.11M
129.45M
119.80M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps